Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. following a class action lawsuit related to the company's performance during a specified class period [1][3]. Group 1: Lawsuit Details - The class action lawsuit was filed for investors who purchased or acquired Altimmune securities between August 10, 2023, and June 25, 2025 [1][2]. - The lawsuit alleges that Altimmune's IMPACT study failed to achieve statistical significance in its primary endpoint of fibrosis reduction, which was attributed to a higher-than-expected placebo response [3]. - Following the announcement of the study results on June 26, 2025, Altimmune's stock price dropped 53%, from $7.71 per share to $3.61 per share, resulting in significant losses for investors [4]. Group 2: Company Background - Altimmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland [2]. - Berger Montague has a long history in securities class action litigation, having represented individual and institutional investors for over five decades [5].

Core Viewpoint - Altimmune faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint analysis [2][3]. Group 1: Trial Results - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, revealing a failure to achieve statistical significance in fibrosis reduction [2]. - The trial showed a positive trend in fibrosis improvement; however, this was overshadowed by a higher-than-expected placebo response [2]. Group 2: Stock Market Reaction - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [3]. Group 3: Legal Proceedings - A court-appointed lead plaintiff has been established, representing the investor with the largest financial interest in the class action lawsuit against Altimmune [4]. - Members of the putative class have the option to serve as lead plaintiff or remain absent, with their ability to share in any recovery unaffected by this decision [4]. Group 4: Whistleblower Information - Faruqi & Faruqi, LLP is encouraging individuals with information regarding Altimmune's conduct, including whistleblowers and former employees, to come forward [5].

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1] Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2] - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant decline of 53.2% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Group 1 - A class action has been filed on behalf of investors who purchased Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023, and June 25, 2025 [1] - Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases [1] - The allegations state that Altimmune misled investors regarding the viability of its IMPACT Phase 2b MASH trial, which failed to achieve statistical significance due to a higher-than-expected placebo response [2] Group 2 - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price dropped from $7.71 per share to $3.61 per share, a decline of over 53% in one day [2] - Shareholders interested in serving as lead plaintiff must submit their papers by October 6, 2025, and do not need to participate in the case to be eligible for recovery [3] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [4]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. on behalf of shareholders who purchased securities between August 10, 2023, and June 25, 2025, alleging that the company misrepresented the results of its IMPACT Phase 2b MASH trial [1][4]. Group 1: Lawsuit Details - The lawsuit claims that Altimmune created a false impression regarding the reliability of information related to the IMPACT Phase 2b MASH trial results, specifically failing to meet a key statistical significance marker for fibrosis reduction [4]. - Altimmune allegedly inflated expectations for positive results while concealing adverse data from the placebo group, which negatively impacted the topline results [4]. - When the true results were disclosed, investors reportedly suffered damages due to the misleading information provided by Altimmune [4]. Group 2: Participation Information - Shareholders who purchased Altimmune securities may be entitled to compensation through a contingency fee arrangement, meaning no out-of-pocket fees or costs are required [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm for more information [3][5]. - A lead plaintiff must file a motion with the court by October 6, 2025, to represent other class members in the litigation [1][3].

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit following the announcement of disappointing results from its IMPACT Phase 2b MASH trial, which led to a significant drop in its stock price [3][4]. Group 1: Company Overview - Altimmune, Inc. is a biopharmaceutical company involved in the development of treatments for liver diseases, specifically focusing on MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) [3]. - The company reported topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which did not meet the expected statistical significance for its primary endpoint related to fibrosis reduction [3]. Group 2: Stock Performance - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price plummeted from $7.71 per share to $3.61 per share, marking a decline of 53.2% in just one day [3]. Group 3: Legal Proceedings - Shareholders who purchased shares of Altimmune during the class period from August 10, 2023, to June 25, 2025, are encouraged to register for participation in the class action lawsuit [4]. - The deadline for shareholders to seek lead plaintiff status is October 6, 2025 [4].

Financial Performance - Altimmune, Inc. reported a quarterly loss of 27 cents per share, which was better than market estimates of a loss of 32 cents per share [1] - The company's quarterly sales amounted to $5.000K [1] Clinical Development - Pemvidutide showed rapid and robust MASH effects, significant weight loss, and impressive safety and tolerability in the recent IMPACT Phase 2b trial [2] - The company is preparing for an End-of-Phase 2 Meeting with the FDA, which will facilitate the transition to Phase 3 development [2] - Full 48-week data is expected to be reported in the fourth quarter, with further updates anticipated as pemvidutide advances [2] Stock Performance and Analyst Ratings - Following the earnings announcement, Altimmune shares increased by 5.7%, trading at $3.8250 [2] - B. Riley Securities analyst Mayank Mamtani maintained a Buy rating but lowered the price target from $20 to $18 [5] - UBS analyst Eliana Merle also maintained a Buy rating, reducing the price target from $26 to $24 [5] - HC Wainwright & Co. analyst Patrick Trucchio reiterated a Buy rating with a maintained price target of $12 [5]

Core Viewpoint - A shareholder class action lawsuit has been filed against Altimmune, Inc. alleging that the company made materially false and misleading statements regarding the results of the IMPACT Phase 2b MASH trial, particularly concerning inflated expectations and undisclosed adverse information related to the placebo group's responses [1] Group 1: Lawsuit Details - The lawsuit claims that Altimmune consistently promoted inflated expectations for positive topline results from the IMPACT Phase 2b MASH trial [1] - It is alleged that the company concealed higher responses in the placebo group, which could negatively impact the topline results [1] Group 2: Shareholder Information - Shareholders who purchased Altimmune shares between August 10, 2023, and June 25, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is October 6, 2025 [3] Group 3: Legal Representation - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3] - The firm has been recognized as an ISS top-rated securities litigation law firm for 2021, 2022, and 2023 [3]

Financial Transactions - ALT5 Sigma 完成了由 World Liberty Financial 牵头的 15 亿美元的注册直接发行和私募 [1] Strategic Partnerships & Leadership Changes - ALT5 Sigma 将采纳 WLFI Treasury Strategy，持有约 WLFI 总供应量的 7.5% [1] - WLFI 的 CEO Zach Witkoff 被任命为 ALT5 的董事长 [1] - Eric Trump 加入 ALT5 担任董事 [1] - Kraken 将担任 ALT5 的资产管理公司 [1]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, which did not meet key statistical significance markers [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Altimmune securities between August 10, 2023, and June 25, 2025 [1]. - The lawsuit claims that Altimmune created a false impression of reliable information regarding trial results, while concealing negative data that would impact the topline results [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering funds for investors [4]. - Investors wishing to serve as lead plaintiff must file their motion by October 6, 2025 [1][3]. Group 3: Trial Results - Altimmune's IMPACT Phase 2b MASH trial failed to achieve statistical significance for the primary endpoint related to fibrosis reduction, contrary to the company's previous claims [5]. - The lawsuit alleges that the company concealed higher responses in the placebo group, which negatively affected the trial's topline results [5].